Market Place
Sourcing Support
FDA Approval of Ensartinib for ALK-Positive NSCLC
19 Dec 2024 //
BUSINESSWIRE
FDA Has Accepted the New Drug Application (NDA) for Ensartinib
13 Mar 2024 //
BUSINESSWIRE
Ensartinib Secured Its First Approval for 1st Line Treatment in ALK+ NSCLC
22 Mar 2022 //
BUSINESSWIRE
Takeda offers value-based pricing for Alunbrig
09 Nov 2021 //
FIERCEPHARMA
Vanderbilt Oncologists Publish Results of First Study
29 Oct 2019 //
BUSINESSWIRE
The Lancet Respiratory Medicine Published Study Shows Ensartinib
18 Oct 2019 //
BIOSPACE
The Lancet Respiratory Medicine Published Study of Ensartinib
17 Oct 2019 //
BUSINESSWIRE
Xcovery Announces Initiation of Phase 2 Clinical Trial for Ensartinib
07 Feb 2018 //
ABCNEWS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.